Triple negative breast cancer+2
RecruitingStudy on Atorvastatin's Role in Enhancing Immunotherapy for Patients with Triple Negative Breast Cancer and Non-Small Cell Lung Cancer
Study on Atorvastatin's Role in Enhancing Immunotherapy for Patients with Triple Negative Breast Cancer and Non-Small Cell Lung Cancer
- Disease:Triple negative breast cancerNon-small cell lung cancer stage IV+1
- Substances:Atorvastatin
Italy- Participants:18–64 years · 65+ years
- Substances:Atorvastatin
- Sponsor:Universita Degli Studi Di Padova
